<DOC>
	<DOCNO>NCT00856804</DOCNO>
	<brief_summary>INDICATION : Patients chronic hepatitis C , genotype 1 non-responders standard treatment hepatitis C. OBJECTIVES : 1. ascertain rate sustain response patient hepatitis C , genotype 1 peginterferon + ribavirin resistance . 2 . To know response rate 12 week 3 . Describe tolerance safety thalidomide combination peginterferon ribavirin . DESIGN OF TEST Pilot Study : The single arm study : 1 . Thalidomide 200 mg peg-interferon alfa 2b ( base weight : 50-120 mcg / week ) + ribavirin ( base weight : 1000-1200mg / day ) Be track 24 week treatment . Suspended treatment 12 week patient fail drop HCV RNA &gt; 2 log . Patients suspend reason , treatment follow 24 week , assess safety parameter . SUBJECT NUMBER : 10</brief_summary>
	<brief_title>Thalidomide Plus Peginterferon Ribavirin Patients With Interferon Resistance</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Men woman non fertile age . HCV RNA detectable serum . Chronic hepatitis C virus noncirrhotic compensate liver disease ( clinical classification accord ChildPugh Grade A ) ( Appendix 1 ) . Genotype 1 . Not respond treatment peginterferon alfa2a combination Ribavirin . Effective contraceptive measure treatment 6 month treatment . Patients follow select treatment : Patients liver biopsy compatible cirrhosis F4 Metav classification . Patients diagnose diabetes basal glycemia high 126 mg / dl Women men childbearing age Treatment systemic antineoplastic immunomodulatory ( include suprafisiológicas dos steroids radiotherapy ) 6 month first dose treatment . Treatment investigational drug 6 week first dose treatment . History evidence pathology associate chronic liver disease HCV . Signs symptoms hepatocellular carcinoma . History evidence bleed due esophageal varix condition consistent decompensated liver disease . neutrophil count &lt; 1500 células/mm3 platelet count &lt; 90,000 células/mm3 Screening . Hb &lt; 12 g / dL woman &lt; 13 g / dL men , time evaluation . Patients baseline increase risk anemia ( eg thalassemia , spherocytosis , history gastrointestinal bleeding , etc. ) . Or presence anemia would medical problem . Patients document presumed coronary artery disease cerebrovascular disease treat opinion investigator , could tolerate adequately sharp decline hemoglobin . serum creatinine &gt; 1.5 time normal upper limit time valuation . History severe psychiatric illness , particularly depression . Is define serious psychiatric illness require treatment antidepressant major tranquilizer therapeutic dos require major depression psychosis , respectively , least 3 month time follow background : attempted suicide , hospitalization due psychiatric illness , period disability due psychiatric illness . History seizure disorder current use major anticonvulsant . History immune disease , chronic lung disease associate limited functionality , serious heart disease , congestive heart failure , advanced atherosclerosis , increase organ transplant sign serious disease , neoplasia , condition deem investigator , prevent patient suitable study . A history thyroid disease poorly control medication prescribe , elevated concentration thyroid stimulate hormone ( TSH ) increase thyroid peroxidase antibody clinical manifestation thyroid disease . Pathology involve risk acute renal function : dehydration ( diarrhea , vomit ) , fever , infectious state / hypotonic severe ( shock , sepsis , urinary infection , neuropathy ) . Evidence severe retinopathy ( eg CMV retinitis , macular degeneration ) . Exploration programanada radiation intravenous administration contrast medium ( IVU , angiography ) . Evidence drug use year prior study . Consumption alcohol . Inability unwillingness give inform consent comply requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Thalidomide</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Interferon resistance</keyword>
	<keyword>Immunomodulators</keyword>
</DOC>